222 related articles for article (PubMed ID: 2417056)
41. Atypical metastasis from prostate cancer. Clinical utility of the immunoperoxidase technique for prostate-specific antigen.
Tell DT; Khoury JM; Taylor HG; Veasey SP
JAMA; 1985 Jun; 253(24):3574-5. PubMed ID: 2582156
[TBL] [Abstract][Full Text] [Related]
42. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
[TBL] [Abstract][Full Text] [Related]
43. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
44. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
45. Medically significant concentrations of prostate-specific antigen in serum assessed.
Bernstein LH; Rudolph RA; Pinto MM; Viner N; Zuckerman H
Clin Chem; 1990 Mar; 36(3):515-8. PubMed ID: 1690092
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
47. The diagnostic value of urinary transferrin compared to serum prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.
van Dieijen-Visser MP; Hendriks MW; Delaere KP; Gijzen AH; Brombacher PJ
Clin Chim Acta; 1988 Sep; 177(1):77-80. PubMed ID: 2460272
[TBL] [Abstract][Full Text] [Related]
48. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
49. Is prostate-specific antigen the most useful marker for screening in prostate cancer?
Delaere KP; Van Dieijen-Visser MP; Gijzen AH; Brombacher PJ
Am J Clin Oncol; 1988; 11 Suppl 2():S65-7. PubMed ID: 2468276
[TBL] [Abstract][Full Text] [Related]
50. Orbital metastasis from prostatic carcinoma. Identification by an immunoperoxidase technique.
Winkler CF; Goodman GK; Eiferman RA; Yam LT
Arch Ophthalmol; 1981 Aug; 99(8):1406-8. PubMed ID: 7020662
[TBL] [Abstract][Full Text] [Related]
51. Detection of tumor cells in bone marrow of patients with prostatic carcinoma by immunocytochemical techniques.
Mansi JL; Berger U; Wilson P; Shearer R; Coombes RC
J Urol; 1988 Mar; 139(3):545-8. PubMed ID: 2449548
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of prostate-specific antigen in untreated prostatic carcinoma.
Oosterom R; Bogdanowicz J; Schröder FH
Eur Urol; 1989; 16(4):253-7. PubMed ID: 2475344
[TBL] [Abstract][Full Text] [Related]
53. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands.
Abrahamsson PA; Lilja H; Falkmer S; Wadström LB
Prostate; 1988; 12(1):39-46. PubMed ID: 2450341
[TBL] [Abstract][Full Text] [Related]
54. Crescentic glomerulonephritis associated with prostatic carcinoma: evidence of immune-mediated glomerular injury.
Haskell LP; Fusco MJ; Wadler S; Sablay LB; Mennemeyer RP
Am J Med; 1990 Feb; 88(2):189-92. PubMed ID: 1689105
[No Abstract] [Full Text] [Related]
55. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
Hetherington JW; Siddall JK; Cooper EH
Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
[TBL] [Abstract][Full Text] [Related]
56. A comparative study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland.
van Dieijen-Visser MP; Delaere KP; Gijzen AH; Brombacher PJ
Clin Chim Acta; 1988 May; 174(2):131-40. PubMed ID: 2454767
[TBL] [Abstract][Full Text] [Related]
57. [Immunohistochemical detection of prostate carcinoma].
Ma WX; Li W
Zhonghua Bing Li Xue Za Zhi; 1989 Mar; 18(1):37-9. PubMed ID: 2476252
[TBL] [Abstract][Full Text] [Related]
58. [Tumor markers of prostate cancer--evaluation of serum PAP and PA].
Miki M
Gan No Rinsho; 1985 May; 31(6 Suppl):664-9. PubMed ID: 2411965
[TBL] [Abstract][Full Text] [Related]
59. An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate.
Siddall JK; Cooper EH; Newling DW; Robinson MR; Whelan P
Eur Urol; 1986; 12(2):123-30. PubMed ID: 2420600
[TBL] [Abstract][Full Text] [Related]
60. Prostatic acid phosphatase in serum and bone marrow in patients with prostatic carcinoma.
Fossà SD; Skinningsrud A; Kaalhus O; Engeset A
Br J Urol; 1983 Jun; 55(3):306-11. PubMed ID: 6850249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
